| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cronos Group Inc., (NASDAQ:CRON) a global cannabinoid company, has reported an increase in net revenue for the first quarter of 2024. The company's net revenue surged by 30%, reaching $25.3 million, driven primarily by sales in Canada and Israel.
Despite this revenue upswing, Cronos posted a net loss of $2.48 million for the quarter, an improvement from the $18.04 million loss reported in the same period last year.
Gross profits rose to $4.48 million, marking a 53% increase year-over-year with a rise in gross margin to 18%.
Cronos's adjusted EBITDA, showing a reduction in losses, decreased to $10.67 million from $15.68 million in Q1 2023. This reduction reflects Cronos's cost-control measures and operational efficiencies implemented during the period.
Additionally, the company's balance sheet showed $855 million in cash and equivalents, positioning Cronos well for ongoing market expansion initiatives.
“Cronos achieved its highest quarterly net revenue from continuing operations on record at $25.3 million, up 30% year-over-year. The top line was propelled by 31% growth year-over-year in Canada, and 27% growth year-over-year in Israel. Cronos' strong first quarter results are a testament to our global team's commitment to excellence,” said Mike Gorenstein, chairman, president and CEO of Cronos.
A deep dive into Cronos's financial data for the three months ended March 31, 2024, compared to the same period in 2023 reveals notable changes in various key metrics.
Consolidated net revenue increased by nearly $5.8 million, or 30%, while the cost of sales rose by $4,237,000, or 26%.
Furthermore, Cronos reported a significant positive swing in net income (loss), reaching ($2,484,000) in 2024 from ($18,035,000) in 2023, reflecting an 86% improvement.
Adjusted EBITDA increased by $5,013,000, or 32%, indicating enhanced operational performance.
While the increases in net revenue, gross profit and cash reserves suggest potential growth and financial stability, investors should note the persistent losses reflected in the net income (loss) figures.
However, Cronos's ongoing strategic initiatives, including the introduction of the PEACE NATURALS brand in the UK and continued innovations across its Spinach and Lord Jones brands in Canada are expected to bolster market presence and contribute to long-term sustainable growth.
Scanning through cannabis spreadsheets can take some time. To learn more about investing, don't miss the opportunity to join us at the 19th Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's future. Secure your tickets now before prices increase by following this link.
Photo: AI-Generated Image.
Posted In: CRON
